Based on the available evidence, a causal relationship between the occurrence of transverse myelitis and the use of durvalumab is considered at least possible; therefore, PRAC agreed that the registration certificate holder (Astra Zeneca AB) for the medicinal product IMFINZI must, within 2 months, amend the instructions for medical use as indicated below (new text underlined).
Section "Posology and method of administration"
| Adverse reaction |
Severity1 |
Dose adjustment |
Treatment with corticosteroids unless otherwise specified |
| Immune-mediated transverse myelitis |
Of any grade |
Discontinue permanently |
Initial dose of 1 to 2 mg/kg/day of prednisone or equivalent, followed by dose reduction |
“Special precautions for use” section
Other immune-mediated adverse reactions
Given the mechanism of action of IMFINZI, other potential immune-mediated adverse reactions may occur. The following immune-related adverse reactions were observed in patients receiving IMFINZI monotherapy: myasthenia, transverse myelitis, myositis, polymyositis, meningitis, encephalitis, Guillain-Barré syndrome, immune thrombocytopenia, non-infectious cystitis and pancreatitis (see the section “Adverse reactions”). Patients should be monitored for signs and symptoms and treated as recommended for other immune-mediated adverse reactions (see the section “Method of administration and doses”).
“Adverse reactions” section
Add the adverse reaction “Transverse myelitis” to the subsection “nervous system disorders” with the frequency “Not known”.
Перелік лікарських засобів, що містять дурвалумаб (durvalumab)та дозволені для медичного застосування на території України (за даними Державного реєстру лікарських засобів станом на 16.11.2022)
To analyze the published information, the applicant must use the original text available at the links: